Phase III Copanlisib in Rituximab-refractory iNHL
To assess the safety of copanlisib.
Lymphoma, Non-Hodgkin
DRUG: Copanlisib (BAY 80-6946)
Number of Participants With Treatment-emergent Adverse Events (TEAE)s, Adverse event data were collected after signing the informed consent until 30 days after the last study drug administration (end of safety follow-up), up to 7 years|Number of Participants With Treatment-emergent Serious Adverse Events (TESAE)s, Serious adverse event data were collected after signing the informed consent until 30 days after the last study drug administration (end of safety follow-up), up to 7 years|Number of Participants With Abnormal Laboratory Parameters, - Above threshold of 10% and reported as TEAEs - any event (Grade 1-4), up to 7 years|Number of Participants With Abnormal Vital Signs, - Reported as TEAEs - worst CTCAE grade total -, up to 7 years
To assess the safety of copanlisib.